VanEck Associates
CORT icon

VanEck Associates’s Corcept Therapeutics CORT Stock Holding History

VanEck Associates’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.1M Sell
139,135
-20,415
-13% -$1.23M 0.01% 574
2026
Q1 		$6.43M Sell
159,550
-1,414
-0.9% -$52.9K ﹤0.01% 735
2025
Q4 		$5.6M Buy
160,964
+38,487
+31% +$3.02M ﹤0.01% 750
2025
Q3 		$10.2M Buy
122,477
+27,183
+29% +$1.97M 0.01% 538
2025
Q2 		$7M Sell
95,294
-14,425
-13% -$1.05M 0.01% 601
2025
Q1 		$12.5M Buy
109,719
+20,753
+23% +$1.26M 0.02% 414
2024
Q4 		$4.48M Buy
+88,966
New +$4.66M 0.01% 730

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VanEck Associates's CORT Position: Q2 2026 in Review

VanEck Associates reduced its Corcept Therapeutics (CORT) stake by 13% in Q2 2026, selling an estimated $1.23M and leaving 139,135 shares worth $12.1M. The position accounts for 0.01% of the portfolio, ranked #574.

VanEck Associates first reported a position in CORT in Q4 2024 and has held it in 7 quarters since. The position peaked at $12.5M in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • VanEck Associates held 139,135 shares of Corcept Therapeutics worth $12.1M as of Q2 2026.
  • VanEck Associates sold 20,415 Corcept Therapeutics shares in Q2 2026, an estimated $1.23M.
  • Corcept Therapeutics made up 0.01% of VanEck Associates's portfolio in Q2 2026, its #574 holding.
  • VanEck Associates first reported a position in Corcept Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • VanEck Associates's Corcept Therapeutics position peaked at $12.5M in Q1 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.